ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
2025-06-30 | 2025-03-31 | 2024-06-30 | ||
|---|---|---|---|---|
| Revenue | 27,767 | 542,709 | - | |
| Research and development | 162,368 | 133,102 | 152,431 | |
| General and administrative | 30,949 | 28,405 | 23,710 | |
| Total operating expenses | 193,317 | 161,507 | 176,141 | |
| Operating (loss) income | -165,550 | 381,202 | -176,141 | |
| Other, net | -176 | 438 | 760 | |
| Interest income | 11,019 | 9,615 | 6,498 | |
| Interest expense | 24,382 | 21,639 | 5,094 | |
| Total other (expense) income | -13,539 | -11,586 | 2,164 | |
| (loss) income before income tax expense and noncontrolling interest | -179,089 | 369,616 | -173,977 | |
| Income tax (benefit) expense | -437 | 1,753 | - | |
| Net (loss) income including noncontrolling interest | -178,652 | 367,863 | -173,977 | |
| Net loss attributable to noncontrolling interest, net of tax | -3,411 | -2,582 | -3,184 | |
| Net (loss) income attributable to arrowhead pharmaceuticals, inc | -175,241 | 370,445 | -170,793 | |
| Basic (in dollars per share) | -1.26 | 2.78 | -1.38 | |
| Basic (in shares) | 139,039,000 | 133,363,000 | 124,199,000 | |
| Diluted (in dollars per share) | -1.26 | 2.75 | -1.38 | |
| Diluted (in shares) | 139,039,000 | 134,484,000 | 124,199,000 | |